The anticancer potential of the NRP1 antagonist was further investigated by determining the effects of NRP1 antagonism on the response of carcinoma cells to a chemotherapeutic agent, 5-fluouracil (5-FU), which possesses a broad spectrum of therapeutic activity against various cancers, including non-small-cell lung cancer. This evidence concerns the gene NRP1 and carcinoma.